Scott Requadt (Talaris)
October 6, 2020 11:21 AM EDTUpdated 05:19 PM
Financing
R&D

Ta­laris Ther­a­peu­tics bags an­oth­er $115M to curb im­muno­sup­pres­sion in or­gan trans­plant pa­tients

Nicole DeFeudis

Editor

Just over a year af­ter se­cur­ing a $100 mil­lion Se­ries A round, Ta­laris Ther­a­peu­tics is back with a $115 mil­lion Se­ries B to fu­el its …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

Up­dat­ed: Roche buys out CAR-T part­ner Po­sei­da for $1B up­front

Up­dat­ed: Am­gen obe­si­ty shot shows 20% weight loss, but dos­ing ques­tions hang over read­out

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

A service from the Financial Times